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Introduction: 
Rapid treatment of patients with anticholinergic toxicity 
in the Ernergcncy Department (ED) has remained problematic for 
many years.  These patients are often agitated. uncooperative, and 
unable to provide a clear history.  Physostigmine is a specific anti- 
dote for anticholinergic toxicity. yet its popularity has waned due to 
controversy surrounding its potential central nervo~is  system and 
cardiac toxicities.  In this brief review, we discuss physostigmine's 
history,  method of action. indications, contraindications,  dosing, 
and its use in the ED. 
Background: 
Physostigmine  is  a naturally-occurring  compound first 
isolated from the extract of the West African Calabar bean (PIzysos- 
tipnza verzoszcn~)  in  1864.  In the same year, a crude Calabar bean 
extract was first used as an antidote for anticholinergic toxicity among 
three prisoners ingesting belladonna.'  Sincc that time. physostig- 
mine has been used to trcat glaucoma, post-operative  ileus.  and 
atropine-induced coma.'  Physostigminc's popularity as an antidote 
grew in the late 1960s and 1970s. particularly for the treatment of 
altered mental status associated with tricyclic antidepressant poi- 
soning."  A  1980 report of asystole complicating physostigmine 
use in two patients with serious tricyclic antidepressant poisoning4 
heralded a retreat fi-om indiscriminate use of the antidote.  More 
recently. opinion has shifted again towards favoring the cautious use 
of physostiglnine as an antidote in selected cases of anticholinergic 
toxicity.' 
Clinical  Pharmacology: 
Acetylcholine is a neurotransmitter that acts at muscar- 
inic and nicotinic receptors of the cholinergic nervous system. Un- 
der notmal conditions, the action of acetylcholine is quickly tcrmi- 
nated by the enzyme acetylcholinesterase (Ach) found in the syn- 
aptic cleft. Drugs and other compounds that are typically classified 
as "anticholinergic" are actually antimuscarinic, since they block the 
effect of acetylcholine at rnuscarinic  receptors within the central 
nervous system, in peripheral ganglia, and on effector organs of the 
autonomic nervous system. namely the exocrine glands (bronchial, 
sweat. lacrimal); and cardiac and smooth muscles.  Such anticholin- 
crgic agents include many antihistamines, antiparkinsonian dnlgs, 
antipsychotics, antispasmodics. tricyclic antidepressants, belladonna 
alkaloids and co~npounds  found in several other poisonous plants 
and fi~ngi.~ 
Physostigmine is a carbamate that reversibly inhibits ace- 
tylcholinesterase.  Physostiglnine acts as a competitive  substrate 
for Ach, allowing acetylcholine to accumulate in the synaptic clefts 
and overcome the blockade of muscarinic receptors by the anticho- 
linergic agents.  Because physostigmine  is a tertiary amine.  it is 
uncharged. lipophilic, and easily crosses the blood-brain barrier.- This 
action allows physostigmine  to reverse toxic CNS effects, whereas 
other carba~nate  dmgs that are charged quaternary a~nines  (such as 
neostigmine and pyridostigmine) will only reverse peripheral signs 
and symptoms. Physostigmine's  ability to reverse central effects led 
to its trade name of AntiliriurnB, since it can reverse the delirium 
associated with anticholinergic toxicity. 
Indications: 
Physostigmine treatment may be indicated for patients with 
moderate to severe anticholinergic poisoning with evidence of both 
peripheral and central toxicity.Vhysostigmine is not generally con- 
sidered a first-line agent, and should probably be reserved for paticnrs 
with potentially life-threatening complications of anticholinergic tox- 
icity  that are unresponsive to standard treatment  regimens.  Such 
complications include severe agitation, seinires. persistent hyperten- 
sion, and heinodyna~nic  compromise secondary to tachycardia (i.e. 
unstable narrow complex dysl-rhythmias). 
In addition to a therapeutic role in clear-cut cases of anticho- 
linergic poisoning, physostigmine also has a potential diagnostic role. 
In patients with altered levels of consciousness, who bv relevant his- 
tory and examination may be suffe~ing  from anticholinergic poisoning, 
a test dose of physostigmine may help to confinn the diagnosis. If the 
patient's mental status significantly improves, more invasive and time- 
consuming diagnostic tests. such as lumbar puncture and cranial com- 
puted tornogaphy, may be avoided;'.' this is particularly true if thc 
paticnt  is then able to identify the substance ingested.  One caution 
must bc noted:  physostigrnine is an "analeptic"  agent and may cause 
non-specific arousal whcn used in the presence of many drugs causing 
depressed mental status. Therefore, minor improvelnents in a patient's 
level of consciousness do not prove that they wcre poisoned with an 
anticholinergic agent. 
Dosing and Precautions: 
The initial dose of physostigmine is  1-2 mg in adults and 
0.02 mglkg in children administered slowly IV over at least 5 minutes. 
Many physicians are even Inore cautious, and utilize 0.5  mg aliquots. 
titrated  slowly to desired effect.  Rapid administration is associated 
with induction of seizures.'  Bccause of its short half-life and rapid 
elimination, the clinical effects of physostigmine are short in duration. 
Repeat  dosing every 20-60 minutes may be needed to correct the 
recul-rence of life-threatening conditions initially treated with the first 
dose."'  Continuous physostigmine infiisions have been reported but 
are not rccommended. Although effective in reversing anticholinergic 
toxicity,  treatment with  physostignlinc can lead to adverse side-ef- 
fects and complications.  Excessive doses of physostigmine may in- 
duce cholinergic toxicity. Prior to administering physostigmine, rcac- 
tion to potential complications should be anticipated.  Urinary outlet 
obstl-~lction  can be prevented by the placement of a Foley catheter and 
bedside s~lction  should be immediately available if needed to clear 
excess salivation, bronchial secretions. or emesis. The patient should 
also be placed on continuous electrocardiographic and pulse oximetry 
monitoring. Close physician supervision during and immediately fol- 
lowing physostigrnine administration is desirable.  Atropine should 
also be rapidly available to counteract excessive cholinergic tone, and 
is administered IV at a dose equal to half the initial dose of physostig- 
mine if such complications occi~r.~  Serious but relatively infrequent 
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chospasm, hake been assoc~ated  w~th  physostlgnnne treatment ' ' 
Contraindications: 
The contraindications to physostigrninc use form one of 
the most controversial issues regal-ding the dn~g.  Several conditions 
listed as contraindications are predictable, as enhancing cholinergic 
tone may exacerbate them, including asthma. chronic obstnlctive 
pulmonary disease. atherosclerotic heart disease. bradycardia, pe- 
ripheral vascular disease, genitourinary and gastrointestinal obstruc- 
tion,'.~~~  Many  sources list tricyclic antidepressant  (TCA) over- 
dose and prolongation of the QRS complex on the ECG 2 0.10 scc 
as absolute contraindications  to physostigmine."  Use in these 
circumstances has been  associated with severe bradyarrhythrnias 
and asystole.' 
The contraindication against physostigmine use in TCA 
overdose patients has reached the status of treatment dogma de- 
spite the fact that it is based on only a few case reports.  We could 
find only 4 reported cases of asystole associated with physostig- 
mine use if the setting of TCA overd~se.'~-~"  In contrast, numerous 
case reports and series have documented successful treatment of 
TCA overdose with physostigmine  without  scrious cardiac side 
effects or coniplications, only a few examples of which are refer- 
enced here,  I .'.'.(,.-  Indeed, physostigrnine had been considered the 
treatment of choice for neurologic arid  cni.diac complications of 
TCA overdose in the early  1970s.'  This disparity niost  likely 
stems from several causes:  I) reporting bias, where positive out- 
comes are more likely to be submitted for publication.  2) the 
cardiotoxicity of TCAs was not as well understood in decades past, 
and the reversal of altered mental status appeared to be the primary 
therapeutic goal: 3) TCA overdose can present with a spectnun of 
disease, where mildly toxic TCA overdose patients may benefit 
from reversal of CNS anticholinergic effects. while seriously poi- 
sonedpatients are more prone to severe bradyarrhythmias and asys- 
tole. The associated clcctrocardiograpliic contraindications to phy- 
sostigmine rely on using the QRS complex as a surrogate marker for 
TCA toxicity."  where a prolonged QRS is presumed to represent a 
patient at risk for complications with physostigminc.  Bums et nl. 
recently reported 5 patients (from a larger case series) with known 
amitriptyline overdose who suffered no serious complications from 
physostigrnine given to reverse anticholinergic effects. But even so, 
all these patients had ECGs documenting a QRS interval less than 
0.10 seconds and were given physostigmine at least 12 hours after 
the initial inge~tion.~  Thus, it appears that TCA overdose alone is 
not an absolute contraindication to physostigmine use. It may still 
be prudent, however, to withhold physostigniinc when there is any 
evidence of QRS interval prolongation. 
Summary - Using Physostigmine  in the ED: 
Since physostigmine is relatively short-acting, and be- 
cause luany aspects of anticholinergic toxicity can bc nianaged by 
standard treatment regimens (e.g.  benzodiazepines for agitation or 
seizures). the ideal role of physostigmine in the ED has not been 
clearly determined.  Physostigmine's prirna~y  role is probably as a 
back-up agent in cases where standard treatment fails for neurologic 
and cardiac con~plications  of anticholinergic toxicity.  Furthennore. 
physostigmine appears to have some benefit over bcnzodiazepines 
in the ~nanagcment  of anticholinergic-induced agitation.'  In some 
cases with features suggestive of anticholinergic toxicity but where 
the differential diagnosis remains broad, physostigmine may con- 
firm the diagnosis and obviate the need for additional invasive or 
expcnsive testing.  Further review and prospective analysis concern- 
ing its use in the setting of TCA overdose or QRS interval prolonga- 
tion is needed to provide clear-cut contraindications. When used with 
proper precautions. however, physostig~nine  can be a valuable tool in 
the ED armamentarium. 
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